Finanzen von Belite Bio, Inc (BLTE)BLTEBelite Bio, Inc

Evaluating the bottom line, Belite Bio, Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -22.10%, provide a clear picture of how effectively BLTE converts its operational activities into shareholder value.

In the context of the broader market, BLTE competes directly with industry leaders such as LGND and RYTM. With a market capitalization of $6.39B, it holds a leading position in the sector. When comparing efficiency, BLTE's gross margin of N/A stands against LGND's 82.24% and RYTM's 26.52%. Such benchmarking helps identify whether Belite Bio, Inc is trading at a premium or discount relative to its financial performance.

Belite Bio has reported significant losses, with net income for 2026/Q2 at -28,412,000 USD and an EPS of -0.71. The company has a very high forward P/E ratio of 416.67, indicating overvaluation relative to earnings expectations.